Stockscreener 앱 받기
40.26
15.54%
-7.1555
Novo Nordisk Adr 주식(NVO)의 최신 뉴스
1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock - The Motley Fool
Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial - CNBC
Novo Nordisk stock forecast: Analysts mixed on Q4 earnings & 2026 guidance - Capital.com
Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - GlobeNewswire Inc.
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Novo Nordisk Balances Oral Wegovy Launch With Legal Fight On Compounds - Sahm
Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens - Sahm
FDA Crackdown Reshapes Wegovy Competition And Risks For Novo Nordisk Investors - Sahm
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside - Sahm
Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending - Finviz
Jim Cramer on Novo Nordisk: "It Seems Eli Lilly's Eating Their Lunch" - Finviz
Novo Nordisk Warning Tests Valuation As Pricing And Competition Intensify - Sahm
Ozempic Maker Novo Nordisk Flags Declining Sales In 2026 - Sahm
Novo Nordisk Faces a Sales Decline in 2026, But Its Portfolio and Pipeline Provide Long-Term Growth - Morningstar
Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? - Finviz
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Novo Nordisk ADR earnings beat by $0.10, revenue topped estimates - Investing.com South Africa
Novo Nordisk's U.S. listing drops significantly after earnings report - medwatch.com
Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz
Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy" - Finviz
Is Novo Nordisk Stock a Bargain Right Now? - Finviz
0.80%
0.28%
자본화:
|
볼륨(24시간):